SEC
PCVX icon

Seven Eight Capital’s Vaxcyte PCVX Stock Holding History

Seven Eight Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,295
Closed -$719K – 464
2024
Q3 		$719K Sell
6,295
-34,805
-85% -$3.14M 0.06% 482
2024
Q2 		$3.1M Buy
+41,100
New +$2.8M 0.32% 66
2023
Q2 		– Sell
-9,636
Closed -$361K – 618
2023
Q1 		$361K Sell
9,636
-2,925
-23% -$124K 0.08% 301
2022
Q4 		$602K Buy
+12,561
New +$493K 0.16% 193

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Seven Eight Capital's PCVX Position: Q4 2024 in Review

Seven Eight Capital sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 6,295 shares — an estimated $719K sold.

Seven Eight Capital first reported a position in PCVX in Q4 2022 and held it in 4 quarters. The position peaked at $3.1M in Q2 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Seven Eight Capital reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 6,295 Vaxcyte shares in Q4 2024, an estimated $719K.
  • Seven Eight Capital first reported a position in Vaxcyte in Q4 2022 and held it in 4 quarters.
  • Seven Eight Capital's Vaxcyte position peaked at $3.1M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.